Cobra Biomanufacturing Plc has entered into a manufacturing development agreement with an undisclosed pharmaceutical partner to produce a protein from the SARS virus in CHO (Chinese Hamster Ovary) cells under cGMP. Simon Saxby, Cobra Biomanufacturing’s chief operating officer, remarked, “We are delighted to work with the company, which is one of the top global players on the biopharmaceutical market. This agreement will leverage Cobra’s significant expertise in manufacturing...